← Eichor
Study identifier: NCT06682819 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)

Condition: Healthy Subjects · Leber Hereditary Optic Neuropathy  ·  Sponsor: Hôpital Necker-Enfants Malades

PhaseNA
Planned participants90
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersYes

About this study

Leber hereditary optic neuropathy (LHON), due to mitochondrial DNA (mtDNA) mutations, is responsible for profound visual impairment. However, there is evidence that optic nerve damage begins before vision declines. There is no biomarker to determine when optic nerve damage begins before visual acuity decline occurs. We hope that the analysis of metabolomics will reveal specific metabolomic profiles and different vitamin B3 and B9 levels depending on whether there are OCT signs of optic nerve damage in healthy patients with mtDNA mutations suggestive of LHON (11778, 3460 or 14484). The existence of an increase in the thickness of the optic fiber layer, whose normal values are well established, constitutes such a sign in favor of optic nerve damage.

This description comes directly from the study's public registry record.

Talk to the study team

christophe Orssaud, MD  ·  33 +156093466  ·  christophe.orssaud@aphp.fr

Pascal Reynier, MD PhD  ·  PaReynier@chu-angers.fr

Always discuss trial participation with your own doctor first.

Locations (1)

HEGPParis, Paris, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06682819